AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research ...
Chosunbiz

Korea showcases cancer advances at AACR with targeted and RNA therapies, CDMO push

Korea showcases cancer advances at AACR with targeted and RNA therapies, CDMO push Korean biotechs spotlight early wins in ...
Game Rant

Monster Hunter Stories 3 Mutation List

Krista McCay is a writer specializing in video game guides and walkthroughs. She first entered the industry in 2022 while studying English at UC Santa Barbara and working part-time as an editor. It ...
The New Yorker

We Are All Constantly Mutating—and That’s a Good Thing

As I am writing this, my DNA is changing. And, as you read this, so is yours. People tend to assume that the genes we inherit from our parents are a fixed blueprint for our growth and development, ...
Monthly Prescribing Reference

Lirafugratinib Gets Priority Review for FGFR2+ Cholangiocarcinoma

A Prescription Drug User Fee Act target date of September 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...